## PHILLIP RESEARCH SDN BHD

199001007125 (198695-X)

B-18-6, Megan Avenue II, No 12, Jalan Yap Kwan Seng, 50450 Kuala Lumpur. Tel No: 03-2783 0300

# Morning Pole Position

#### All market data as at previous trading day

#### **Market indices**

| Indices            | Last      | Daily chg   | YTD chg%   |
|--------------------|-----------|-------------|------------|
| Local              |           |             |            |
| FBM KLCI           | 1,382.47  | 9.11        | -11.81     |
| FBM Emas           | 9,858.32  | 59.80       | -12.83     |
| FBM Syariah        | 9,854.79  | 87.25       | -19.64     |
| FBM Small Cap      | 13,659.88 | 42.29       | -13.33     |
| FBM ACE            | 4,652.10  | 34.45       | -27.53     |
| F4G BM             | 797.91    | 4.76        | -9.36      |
| F4G BMS            | 809.93    | 8.06        | -17.57     |
| Funds Flows        |           | Net Bu      | ıy (MYR'm) |
| Local Institutions |           |             | 111.5      |
| Local Retails      |           |             | -12.2      |
| Foreign            |           |             | -99.3      |
| Foreign            |           |             |            |
| Dow Jones          | 29,634.83 | -403.89     | -18.45     |
| S&P 500            | 3,583.07  | -86.84      | -24.82     |
| Nasdaq             | 10,321.39 | -327.76     | -34.03     |
| FTSE               | 6,858.79  | 8.52        | -7.12      |
| Hang Seng          | 16,587.69 | 198.58      | -29.11     |
| Nikkei             | 27,090.76 | 853.34      | -5.91      |
| Shanghai Cl        | 3,071.99  | 55.63       | -15.60     |
| Strait Times       | 3,039.61  | -0.84       | -2.69      |
| Currencies         |           |             |            |
| BNM Middle Rate    | Last      | t Daily chg | YTD %      |
| (5pm)              |           |             |            |
| USD / MYR          | 4.7030    |             |            |
| GBP / MYR          | 5.3033    |             |            |
| JPY100 / MYR       | 3.1845    | 5 -0.0108   | -12.00     |

#### EUR/MYR 4.5854 0.0290 -2.73 7.04 SGD / MYR 3.3026 0.0321 CNY / MYR 0.0013 0.6538 -0.14 AUD / MYR 2.9620 0.0134 -2.13 **Bond Yield Movements**

|     |          | Yield | Daily Change<br>(bps) |
|-----|----------|-------|-----------------------|
| MGS | 3- year  | 3.93  | 1                     |
|     | 10- year | 4.46  | 1                     |
| GII | 3- year  | 3.96  | 8                     |
|     | 10- year | 4.50  | 1                     |
| UST | 2- year  | 4.48  | 1                     |
|     | 10- year | 4     | 3                     |

#### **Commodities**

|                               | Last     | Daily<br>chg | Daily<br>chg % |
|-------------------------------|----------|--------------|----------------|
| CPO (3 <sup>rd</sup> month)   | 3,866.00 | 165          | 4.46           |
| Brent (1 <sup>st</sup> month) | 91.46    | -3.23        | -3.41          |
| Gold (spot)                   | 1,641.76 | -24.04       | -1.44          |
|                               |          |              |                |

Source: Treasury.gov, Bursa and BNM

# | 17<sup>th</sup> October 2022 |

#### **FBMKLCI** and statistics



#### Market Turnover

| Vol (m shrs)  | 2,253 |  |
|---------------|-------|--|
| Value (MYR m) | 1,760 |  |

| Top 5 Value | Last  | Daily<br>chg % | Value<br>(MYR m) |
|-------------|-------|----------------|------------------|
| PBBANK      | 4.200 | 0.72           | 94.859           |
| CIMB        | 5.300 | 0.00           | 91.624           |
| PCHEM       | 8.550 | 1.18           | 81.986           |
| MAYBANK     | 8.450 | -0.24          | 77.420           |
| TOPGLOV     | 0.690 | 0.00           | 70.568           |

| Top 5 Gainers | Last  | Daily<br>chg % | Value<br>(MYR m) |
|---------------|-------|----------------|------------------|
| MNC           | 0.010 | 100.00         | 0.001            |
| ZENTECH       | 0.030 | 50.00          | 0.092            |
| MLAB          | 0.015 | 50.00          | 0.018            |
| DOLPHIN       | 0.020 | 33.33          | 0.025            |
| PASUKGB       | 0.020 | 33.33          | 0.019            |

| Top 5 Losers | Last  | Daily<br>chg % | Value<br>(MYR m) |
|--------------|-------|----------------|------------------|
| NEXGRAM      | 0.005 | -50.00         | 0.003            |
| PHB          | 0.005 | -50.00         | 0.000            |
| AT           | 0.010 | -33.33         | 0.014            |
| ANZO         | 0.010 | -33.33         | 0.005            |
| CHINAETF-USD | 0.903 | -30.00         | 0.000            |

| Top 5 DBT | Value<br>(MYR m) | Volume<br>(m shares) | Price<br>(MYR) |
|-----------|------------------|----------------------|----------------|
| BJFOOD    | 32.000           | 40.000               | 0.875          |
| WIDAD     | 4.980            | 18.200               | 0.395          |
| OVH       | 2.816            | 18.165               | 0.15           |
| KAB       | 7.107            | 17.335               | 0.415          |
| NOVAMSC   | 1.362            | 14.336               | 0.095          |

#### **Market Pulse**



Source: Chart created using tradingview.com's tools, PRSB

The KLCI extended its losses for the week amidst weak global market sentiment ahead of the U.S. inflation data release and lack of direction on the local political front. It close at 1,382.47 pts with -23.53 pts (-1.67%) as it dragged by 25 losers compared to 5 gainers for the week. Dialog and Axiata were the largest losers, shredding 10.20% and 9.06% respectively while the glove counters seen some rotational play as Hartalega and Top Glove gained 11.24% and 6.98% respectively.

In the U.S. market, the major indexes were mostly lower this week as investors weighed inflation data and its implications for the Fed policy. Even with the release of the first major third-quarter corporate earnings reports, all eyes seemed to remain on the macroeconomic environment, particularly inflation. Unrelenting inflation has dashed hopes for a quick pivot away from aggressive interest rate hikes by the Fed, which in turn is undermining the U.S. corporate earnings outlook for 2023 and fuelling debate about whether the next major financial crisis might be on the way. On top of that, President Xi Jinping defends on Zero Covid Strategy during his opening speech at the 20<sup>th</sup> National Party Congress offers less comfort to the global supply chain situation and China economy outlook.

The local market sentiment for the week is likely to remain weak as uncertainty continue to ensue on the local political front. Although KLCI close below the 1,400 level for the week, we think that 1,378.37 level will serve as a strong support to provide a chance for KLCI to stage a rebound for the week. This is also supported by RSI heading toward oversold territory and potentially stage a rebound. Technically, the KLCI may continue to trade in between 1,408.83 pts and 1,378.37 pts level. Our Picks in Exhibit 1.

| Company        | Ticker   | Rating     | Price (MYR) | TP (MYR) | Upside (%) |
|----------------|----------|------------|-------------|----------|------------|
| Fundamental    |          |            |             |          |            |
| Bermaz Auto    | BAUTO MK | Buy        | 1.90        | 2.45     | 28.95      |
| Guan Chong     | GUAN MK  | Outperform | 2.05        | 2.78     | 35.61      |
| Technical      |          |            |             |          |            |
| QL Resources   | QLG MK   | Outperform | 5.02        | 5.77     | 14.94      |
| Opcom Holdings | OHB MK   | Buy        | 0.850       | 1.24     | 45.88      |
|                |          |            |             |          |            |

#### Exhibit 1: Our Picks

| KSL Holdings  | KSL MK         | Buy        | 0.750    | 0.96     | 28.00 |
|---|----------------|------------|----------|----------|-------|
| Gamuda  | GAM MK         | Outperform | 3.90     | 4.30     | 10.26 |
| Chin Well Holdings                                  | CWH MK         | Outperform | 1.66     | 2.00     | 20.48 |
| Supercomnet Technologies                            | SCT MK         | Outperform | 1.56     | 1.73     | 10.90 |
| Pentamaster Corporation                             | PENT MK        | Buy        | 3.72     | 5.26     | 41.40 |
| Formosa Prosonic Industries                         | FOR MK         | Buy        | 2.89     | 3.92     | 35.64 |
| Kerjaya Prospek Group                               | KPG MK         | Outperform | 1.19     | 1.39     | 16.81 |
| MMS Ventures  | MMSV MK        | Buy        | 0.640    | 1.20     | 87.50 |
| FM Global Logistics Holdings                        | FMH MK         | Buy        | 0.525    | 0.82     | 56.19 |
| Hibiscus Petroleum                                  | HIBI MK        | Buy        | 0.94     | 1.32     | 41.18 |
| OSK Holdings  | OSK MK         | Buy        | 0.86     | 1.12     | 30.99 |
| UWC   | UWC MK         | Buy        | 3.52     | 5.03     | 42.90 |
| Dayang Enterprise                                   | DEHB MK        | Buy        | 1.11     | 1.44     | 29.73 |
| CTOS Digital  | CTOS MK        | Buy        | 1.32     | 1.78     | 34.85 |
| Ancom Nylex   | ANC MK         | Buy        | 1.00     | 1.24     | 24.00 |
| BP Plastics Holdings                                | BPP MK         | Buy        | 1.40     | 1.80     | 28.57 |
| CCK Consolidated Holdings                           | CCK MK         | Outperform | 0.61     | 0.71     | 17.36 |
| Vitrox Corp Bhd                                     | VITRO BHD      | Buy        | 6.96     | 7.88     | 13.15 |
| Pecca Group BHd                                     | PECCA MK       | Buy        | 0.83     | 1.16     | 40.00 |
| Nova Wellness Group Bhd                             | NOVA MK        | Outperform | 0.91     | 1.07     | 17.03 |
| Duopharma Biotech Bhd                               | DBB MK         | Outperform | 1.30     | 1.44     | 10.77 |
| Mega First Corp                                     | MFCB MK        | Outperform | 3.20     | 3.63     | 13.28 |
| ETF   |                |            |          |          |       |
| MyETF Dow Jones U.S.<br>Titans 50                   | METFUS50<br>MK | Buy        | USD 1.65 | USD 1.93 | 17.12 |
| MyETF MSCI SEA Islamic<br>Dividend                  | MEMSID MK      | Buy        | 0.79     | 0.92     | 16.28 |
| Principal FTSE ASEAN 40<br>Malaysia ETF             | CIMBA40 MK     | Buy        | 1.60     | 1.80     | 12.48 |
| Principal FTSE China 50 ETF                         | CIMBC25 MK     | Buy        | 1.15     | 1.39     | 21.17 |
| TradePlus HSCEI Daily (2x)<br>Leveraged Tracker     | HSCEI2XL MK    | Strong Buy | 0.48     | 0.85     | 77.89 |
| TradePlus NYSE FANG+<br>Daily (-1x) Inverse Tracker | FANG1XI MK     | Buy        | 1.90     | 1.86     | -2.11 |

Source: Bursa, Bloomberg, PRSB, price as of 14<sup>th</sup> October 2022

#### Malaysian news highlights

#### • Govt has money to implement Budget 2023 — PM.

Prime Minister Datuk Seri Ismail Sabri Yaakob on Sunday said the government has money to implement Budget 2023, tabled on Oct 7, with the largest budget ever prepared involving an allocation of RM372.3 billion. "When we announced the budget in Parliament, that meant we already had the money to implement everything that we promised... the money is already there but [the Budget] has not been passed yet. (Source: <u>TheEdgeMarkets</u>)

### Global news highlights

• Fed Officials Look at Higher Peak for Rates as Inflation Endures.

Federal Reserve policymakers suggested that they're prepared to raise interest rates higher than previously planned, though not necessarily at a faster pace, to defeat persistent high inflation. Kansas City Fed President Esther George said Friday that officials should raise rates to a restrictive level while avoiding too much haste, which could "disrupt financial markets and the economy in a way that ultimately could be self-defeating." (Source: <u>Bloomberg</u>)

#### • US Retail Sales Stagnate as Inflation, Rates Hit Consumers.

The value of overall retail purchases were little changed in September after an upwardly revised 0.4% gain in August, Commerce Department data showed Friday. Excluding gasoline, retail sales were up 0.1%. The figures aren't adjusted for inflation. (Source: <u>Bloomberg</u>)

#### • Natural Gas Caps Its Longest US Losing Streak in 21 Years.

US gas has tumbled for eight straight weeks, with prices down more than 30% from a 14-year high in August. Futures in Europe, a region increasingly reliant on American supplies of the heating and power-plant fuel after Russia's invasion of Ukraine, are also down on rising stockpiles. (Source: Bloomberg)

#### • UK corporation tax to rise to 25% on PM Truss's U-turn.

Britain's corporation tax will rise to 25%, said Prime Minister Liz Truss after she sacked finance minister Kwasi Kwarteng and U-turned on a programme of tax cuts on Friday. In a Sept 23 "minibudget", Kwarteng had said corporation tax would be frozen at 19%, scrapping a rise to 25% planned by his predecessor, alongside a raft of other unfunded tax cuts which have since roiled financial markets. (Source: <u>TheEdgeMarkets</u>)

#### • Bank of England Says More People Are Hoarding Cash After Covid.

The Bank of England said more people are hoarding cash as a way of protecting wealth after the pandemic. The UK central bank said the value of notes and coins in circulation rose 17% to £12.3 billion (\$13.9 billion) at the end of June 2022 compared with early 2020, when coronavirus lockdowns were in force. (Source: Bloomberg)

#### • Xi Sticks to Economic Goals Calling Development Top Priority.

At the opening of the 20th party congress in Beijing, in which Xi is likely to secure a third term in power, he echoed development-first phrasing used in congress addresses by every party leader since Jiang Zemin in 2002. "Development is the party's top priority in governance," he said. (Source: Bloomberg)

#### • Xi Defends Covid Zero Without Showing China Path Out of Pandemic.

Chinese President Xi Jinping again defended his signature Covid Zero policy, while avoiding setting a timeline on when the strategy that's become a source of growing frustration for the public will be changed. "We have put people first and put lives first, and upheld 'dynamic Covid Zero' without wavering," he said Sunday in a speech at the opening of the ruling Communist Party's twice-a-decade congress in Beijing. (Source: <u>Bloomberg</u>)

#### • Key Takeaways From Xi Jinping's Two-Hour Speech.

President Xi Jinping delivered a wide-ranging speech Sunday laying out the Communist Party's agenda for China over the next five years, covering everything from Taiwan to tech policy. (Source: Bloomberg)

#### • India's Rupee Will Endure Dollar Strengthening, Sitharaman Says.

The Indian currency will withstand the recent strengthening of the dollar, Finance Minister Nirmala Sitharaman said, reiterating a central bank forecast that the South Asian economy will grow at 7% in the year to March, 2023. "The Indian rupee has performed much better than many other emerging market currencies," Sitharaman said at a media briefing in Washington D.C. late on Saturday. The country's central bank was working to contain the rupee's volatility, she said, adding that the "rupee will find its own level." (Source: <u>Bloomberg</u>)

#### • South Korea Cooperating With US on Chips, Still Has Concerns.

South Korea's trade minister said key chip producers Samsung Electronics Co. and SK Hynix Inc. won approval from the US to keep operating in China, but that concerns remain over the impact of Washington's sweeping new restrictions. "South Korea is fully cooperating with the US," Ahn Dukgeun said in an interview with Bloomberg News, explaining that the US decisions were based on an understanding that Korean chipmakers' fabs in China are crucial in stabilizing the global supply chain. (Source: <u>Bloomberg</u>)

#### • Southeast Asia central banks dig into toolkit to fight risks.

Policymakers across Southeast Asia are reaching for both conventional and unconventional instruments available in their toolbox to stem plunging currencies and cool price gains. While the region's problems are middling compared to some neighbours in the South, countries face their biggest challenges in decades. The Philippine peso retraced an all-time low this week, while the Malaysian ringgit drifted to the weakest in almost 25 years, as a stronger dollar ups the risk of imported inflation. (Source: <u>TheEdgeMarkets</u>)

#### • Singapore says Covid-19 XBB subvariant's infection wave to peak by mid-November.

Covid-19 cases have been on the rise over the past month in Singapore, mainly due to the Omicron XBB subvariant, with the infection wave expected to peak around mid-November. The republic's Ministry of Health (MOH) said it has been closely tracking the trajectory of the current wave, and has taken steps to ensure that Singapore's healthcare capacity remains protected. (Source: <u>TheEdgeMarkets</u>)

#### • Philippine Central Bank Monitors Peso for Signs of Speculation.

The Philippine central bank is monitoring currency transactions for potential speculation as part of its efforts to mitigate the peso's volatility, Finance Secretary Benjamin Diokno said. "The central bank has initiated actions to moderate sudden movements in the peso, including participation in the foreign-exchange market as well as looking into possible cases of speculative activities," said Diokno, who sits on the monetary authority's board. (Source: <u>Bloomberg</u>)

#### **Corporate news**

#### • EPF ups shares in AMMB to 11.27%.

Employees Provident Fund increased its stake in banking group AMMB Holdings Bhd to 11.27%. The institutional fund bought five million shares on Tuesday (Oct 11), bringing its cumulative shareholding to 373.19 million, up 57.94 million shares from 315.25 million shares (9.52% stake) on June 21. EPF has been buying shares in the banking group over the past three months. Since July, it has purchased a total of 67.8 million shares. (Source: <u>TheEdgeMarkets</u>)

#### • No appeal from US fund over dismissal of suit against IHH Healthcare.

No appeal has been filed by Emqore Envesecure Private Capital Trust against a court decision to dismiss the US fund's lawsuit seeking over US\$6.5 billion (RM30.56 billion) in damages from IHH Healthcare Bhd and others. Disclosing this in a stock exchange filing on Friday (Oct 14), IHH said

Empore had a 30-day window to file an appeal against the New Jersey District Court's order dated Sept 7. "IHH will make further announcements as and when there are material developments on the above matter," it added. (Source: <u>TheEdgeMarkets</u>)

• All eyes on other concessionaires following Gamuda's successful highway concessions restructuring.

Now that Gamuda Bhd's highway concessions have been successfully restructured, all eyes are now on the other concessionaires, including IJM Corp Bhd. The news of Gamuda's successfully restructured highway concession on Thursday (Oct 13) came on the same day as an announcement by caretaker Prime Minister Datuk Seri Ismail Sabri Yaakob that the government has agreed with the proposal to restructure four highway toll concession companies under Prolintas to reduce the toll rates of the highways involved. (Source: <u>TheEdgeMarkets</u>)

• Leong Hup unit gets another extension to respond to MyCC's poultry feed price-fixing allegations.

The Malaysia Competition Commission (MyCC) has granted Leong Hup International Bhd's unit another extension to submit its representation in response to the watchdog's proposed decision on poultry feed price-fixing. The poultry player said MyCC has extended the deadline for its wholly owned subsidiary, Leong Hup Feedmill Malaysia Sdn Bhd, to file its written representations to Dec 19. This came after LFM received MyCC's amended proposed decision and supplementary proposed decision on Tuesday (Oct 11), Leong Hup said in a bourse filing. (Source: <u>TheEdgeMarkets</u>)

• TNB gets approval to refurbish Sg Perak hydropower plant.

Tenaga Nasional Bhd's unit has obtained approval from the Energy Commission to refurbish Sungai Perak hydroelectric power plants with a capacity of 650.75MW. TNB said the project, dubbed Hydro Life Extension Programme, involves six power stations comprising 18 units, with refurbishment works commencing in 2024. The first unit is expected to be in commercial operation in 2025 under the new 40-year power purchase agreement, said the utility giant in a stock exchange filing on Friday (Oct 14). (Source: <u>TheEdgeMarkets</u>)

• TNB: ICPT-based electricity generation cost recovery at RM5.8b for July-December 2022.

Malaysian Government-controlled utility Tenaga Nasional Bhd (TNB) expects to recover RM5.8 billion between July and December 2022 under its electricity generation cost recovery scheme based on the imbalance cost pass-through (ICPT) mechanism. "The ICPT mechanism allows TNB to remain neutral to fuel price vagaries, as it allows us to pass through any variations in generation cost in the form of rebates or surcharges," TNB said in its latest corporate presentation. (Source: <u>TheEdgeMarkets</u>)

#### • MHB unit inks MOU to speed up job opportunities in energy sector.

Malaysia Marine and Heavy Engineering Sdn Bhd (MMHE) has signed a memorandum of understanding (MOU) with Gigih Avenue Sdn Bhd (GASB) to collaborate in a programme to provide training and certification in welding and employment opportunities for eligible local welders. The collaboration amplifies efforts to develop a technical-skilled workforce among local talents, in order to build a manpower supply for the oil and gas and various energy sectors in Malaysia. (Source: <u>TheEdgeMarkets</u>)

### **Entitlements**

| Stock<br>Code | Stock<br>Name | Entitlements | Description             | Ex-Date    | Lodgement<br>Date | Payment/<br>Cessation<br>Date |
|---------------|---------------|--------------|-------------------------|------------|-------------------|-------------------------------|
| 3026          | FBBHD         | RM0.0140     | Interim Dividend        | 18/10/2022 | 19/10/2022        | 28/10/2022                    |
| 5081          | EIG           | RM0.0050     | Final Dividend          | 18/10/2022 | 19/10/2022        | 18/11/2022                    |
| 9385          | LAYHONG       | RM0.0030     | Final Dividend          | 18/10/2022 | 19/10/2022        | 16/11/2022                    |
| 3255          | HEIM          | RM0.4000     | Interim Dividend        | 19/10/2022 | 20/10/2022        | 11/11/2022                    |
| 3053          | CCIB          | RM0.0064     | Interim Dividend        | 20/10/2022 | 21/10/2022        | 3/11/2022                     |
| 5007          | CHINWEL       | RM0.0800     | Second Interim Dividend | 21/10/2022 | 25/10/2022        | 24/11/2022                    |

#### DISCLAIMER

Legal and Regulatory Notices (Electronic Communications) © 2018 PRSB.

#### Important disclosures

This research report is strictly confidential and has been prepared for information purposes only by Phillip Research Sdn Bhd ("PRSB"), a subsidiary of Phillip Capital Holdings Sdn Bhd ("PCH") and is meant for circulation to its clients and clients of other subsidiaries companies of PCH particularly Phillip Mutual Berhad ("PMB"), Phillip Capital Management Sdn Bhd ("PCM"), Phillip Wealth Planners Sdn Bhd ("PWP") and Phillip Capital Sdn Bhd ("PCSB") (collectively refer to as Phillip Group other licensed intermediaries ("PGOLI")) only or such other persons as may be deemed eligible to receive such research report, information or opinion contained herein. Neither the publication/communication nor any portion hereof may be reprinted, distributed, sold, resold, redistributed, copied, reproduced, published, republished, displayed, posted or transmitted in any form or media or by any means without the written consent of PRSB.

The policy of PRSB is to only publish research that is impartial, independent, clear, fair, and not misleading. Analysts never receive compensation from companies they cover. Regulations or market practice of some jurisdictions/markets prescribe certain disclosures to be made for certain actual, potential or perceived conflicts of interests relating to a research report as below. This research disclosure is for your information only and does not constitute any recommendation, representation or warranty. Absence of a disclosable position should not be taken as endorsement on the validity or quality of the research report or recommendation.

To maintain the independence and integrity of PRSB's research, PGOLI activities such as fund management, dealing in securities (restricted to unit trust and private retirement scheme), dealing in derivatives, clearing for derivatives, financial planning and research business lines are distinct from one another. This means that PRSB is not part of and does not report to any of PGOLI. Accordingly, PGOLI does not supervise nor control the activities of PRSB's research analysts. PRSB's research analysts report to the Head of Research, who in turn report to PRSB's senior management.

PRSB and PGOLI have in place internal controls designed to manage conflicts of interest that may arise as a result of PGOLI engaging in fund management, dealing in securities (restricted to unit trust and private retirement scheme), dealing in derivatives, clearing for derivatives, financial planning and PRSB activities. Some examples of these controls include: the use of information barriers and other information controls designed to ensure that confidential information is only shared on a "need to know" basis and in compliance with PRSB and PGOLI's Chinese Wall policies and procedures; measures designed to ensure that interactions that may occur among PRSB's research personnel, fund management, dealing in securities (restricted to unit trust and private retirement scheme), dealing in derivatives, clearing for derivatives, and financial planning, PGOLI's financial product issuers and PRSB's research analysts do not compromise the integrity and independence of PRSB's research.

Neither analysts nor their household members/associates/may have a financial interest in, or be an officer, director or advisory board member of companies covered by the analyst unless disclosed herein. In circumstances where an analyst has a pre-existing holding in any securities under coverage, those holdings are grandfathered and the analyst is prohibited from trading such securities up to the date of the publication of this research report.

Unless specified otherwise, PRSB did not receive investment banking/non-investment banking income from, and did not manage/co-manage a public offering for, the listed company during the past 12 months, and it does not expect to receive investment banking compensation from the listed company within the coming three months. Unless mentioned otherwise, PRSB does not own a material disclosable position, and does not make a market, in the securities.

We hereby certify that the views expressed in this research report accurately reflect our views about the securities and/or the issuers and that no part of our compensation were or will be directly or indirectly related to the specific recommendation or views contained in this report or to any investment banking relationship with the subject company covered in this report (for the past one year) or otherwise any other relationship with such company which leads to receipt of fees from the company except in ordinary course of business of the company. We hereby confirm that our analyst(s) has/have not been placed under any undue influence, intervention or pressure by any person(s) in compiling this research report. This report is prepared without any intention to raise, lower or maintaining the price of the securities covered or to induce the recipient to buy or sell the securities covered. In addition, our analyst(s) included herein attest that he/she/they was/were not in possession of any material, non-public price sensitive information regarding the subject company at the time of publication of the report. Save from the disclosure below (if any), we are not aware of any material conflict of interest.

Key to PRSB investment ratings:

Equity:

BUY: Total stock return (including dividends) expected to exceed 20% annually;

O-PF: Total expected return below 20% annually but exceeding market return;

U-PF: Total expected return positive but below market return;

SELL: Total return expected to be negative.

For relative performance, we benchmark the 12-month total forecast return (including dividends) for the stock against the 12-month forecast return (including dividends) for the market on which the stock trades.

ETFs (Criteria applies to rating assignments from 16th December 2019):

STRONG BUY: Total return (including dividends) expected to exceed 20% annually;

BUY: Total expected return below 20% but exceed 5% or then 1-year rate, whichever is higher;

SELL: Total return of not more than 5% or then 1-year rate, whichever is higher.

The ratings are based on the forecast total return (including dividends) over the next 12 months. Funds:

The rating a mathematical scoring system that include risks (standard deviation, Sharpe Ratio) and returns (1year, 3-year, 5-year and consistency)BUY: Total return (including income distribution) is positive and above peers' average while risk factors are low;

O-PF: Total return is positive and above peers' average but has higher risk factors; SELL: Total return is negative.

For a history of the recommendations and price targets for companies mentioned in this report, as well as company specific disclosures, please write to: Phillip Research Sdn Bhd, B-18-6, Block B Level 18, Megan Avenue II, 12 Jalan Yap Kwan Seng, 50450 Kuala Lumpur, Malaysia.

The information, opinions and estimates herein are not directed at, or intended for distribution to or use by, any person or entity in any jurisdiction where doing so would be contrary to law or regulation or which would subject PRSB and/or its associate companies to any additional registration or licensing requirement within such jurisdiction. The information and statistical data herein have been obtained from sources we believe to be reliable. Such information has not been independently verified and we make no representation or warranty as to its accuracy, completeness or correctness. Any opinions or estimates herein reflect the judgment of PRSB at the date of this publication/communication and are subject to change at any time without notice. Where any part of the information, opinions or estimates contained herein reflects the views and opinions of a sales person (include but not limited to Financial Planners and Marketing Representative or a non-analyst), such views and opinions may not correspond to the published view of PRSB. This is not a solicitation or any offer to buy or sell. This publication/communication is for information purposes only and does not constitute any recommendation, representation, warranty or guarantee of performance. Any price target given in the report may be projected from one or more valuation models and hence any price target may be subject to the inherent risk of the selected model as well as other external risk factors. This is not intended to provide professional, investment or any other type of advice or recommendation and does not take into account the particular investment objectives, financial situation or needs of individual recipients. Before acting on any information in this publication/communication, you should consider whether it is suitable for

your particular circumstances and, if appropriate, seek professional advice, including tax advice. PRSB, and PGOLI do not accept any responsibility and cannot be held liable for any person's use of, or reliance on the information and opinions contained herein. To the extent permitted by applicable securities laws and regulations, PRSB accepts no liability whatsoever for any direct or consequential loss arising from the use of this publication/communication or its contents. Where the publication does not contain ratings, the material should not be construed as research but is offered as factual commentary. It is not intended to, nor should it be used to form an investment opinion about the non-rated companies.

Subject to any applicable laws and regulations at any given time, PRSB, PGOLI and their respective affiliates or companies or individuals connected with PRSB may have used the information contained herein before publication and may have positions in, may from time to time purchase or sell or have a material interest in any of the securities mentioned or related securities, or may currently or in future have or have had a business or financial relationship with, or may provide or have provided investment banking, capital markets and/or other services to, the entities referred to herein, their advisors and/or any other connected parties. As a result, investors should be aware that PRSB, PGOLI and/or their respective affiliates or companies or such individuals may have one or more conflicts of interest. Regulations or market practice of some jurisdictions/markets prescribe certain disclosures to be made for certain actual, potential or perceived conflicts of interests relating to research reports. Details of the disclosable interest can be found in certain reports as required by the relevant rules and regulation. Disclosures therein include the position of PRSB and PGOLI only. Unless specified otherwise, PRSB did not receive any compensation or other benefits from the subject company covered in this publication/communication.

The analysts/contributors to this publication/communication may be employed by any relevant PGOLI entity, which is different from the entity that distributes the publication/communication in the respective jurisdictions.

PRSB, PGOLI and/or its officers, directors and employees, may, to the extent permitted by applicable law and/or regulation, deal as principal, agent, or otherwise, or have long or short positions in, or buy or sell, the securities, commodities or instruments, or options or other derivative instruments based thereon, of issuers or securities mentioned herein. PGOLI may also act as market maker or liquidity provider (within the meaning of applicable regulations in the UK) in the financial instruments of the issuer. Where the activity of market maker is carried out in accordance with the definition given to it by specific laws and regulations of the US or other jurisdictions, this will be separately disclosed within the specific issuer disclosures.

Investors should not consider this report as only a single factor in making their investment decision and, as such, the report should not be viewed as identifying or suggesting all risks, direct or indirect, that may be associated with any investment decision. PRSB produces a number of different types of research product including, among others, fundamental analysis and quantitative analysis; recommendations contained in one type of research product may differ from recommendations contained in other types of research product, whether as a result of differing time horizons, methodologies or otherwise. PRSB and PGOLI publishes research product in a number of different ways including the posting of product on the PGOLI portals and/or distribution directly to clients. Different groups of clients may receive different products and services from the research department depending on their individual requirements.

Figures presented herein may refer to past performance or simulations based on past performance which are not reliable indicators of future performance. Where the information contains an indication of future performance, such forecasts may not be a reliable indicator of future performance. Moreover, simulations are based on models and simplifying assumptions which may oversimplify and not reflect the future distribution of returns. Any figure, strategy or index created and published for illustrative purposes within this report is not intended for "use" as a "benchmark".

Certain securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of, or income derived from, the investment.

With respect to Fixed Income Research: Recommendations fall into two categories: tactical, which typically last up to three months; or strategic, which typically last from 6-12 months. However, trade recommendations may be reviewed at any time as circumstances change. 'Stop loss' levels for trades are also provided; which, if hit, closes the trade recommendation automatically. Prices and yields shown in recommendations are taken at the time of submission for publication and are based on either indicative Bloomberg, Reuters or PGOLI prices or yields at that time. The prices and yields shown are not necessarily those at which the trade recommendation can be implemented.

The securities described herein may not have been registered under the US Securities Act of 1933 (the '1933 Act'), and, in such case, may not be offered or sold in the US or to US persons unless they have been registered under the 1933 Act, or except in compliance with an exemption from the registration requirements of the 1933 Act. Unless governing law permits otherwise, any transaction should be executed via PhillipCapital Group entity in your home jurisdiction.